Cargando…
CETP inhibitor evacetrapib enters mouse brain tissue
High levels of plasma cholesterol, especially high levels of low-density lipoprotein cholesterol (LDL-C), have been associated with an increased risk of Alzheimer’s disease. The cholesteryl ester transfer protein (CETP) in plasma distributes cholesteryl esters between lipoproteins and increases LDL-...
Autores principales: | Phénix, Jasmine, Côté, Jonathan, Dieme, Denis, Recinto, Sherilyn J., Oestereich, Felix, Efrem, Sasen, Haddad, Sami, Bouchard, Michèle, Munter, Lisa Marie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390775/ https://www.ncbi.nlm.nih.gov/pubmed/37533630 http://dx.doi.org/10.3389/fphar.2023.1171937 |
Ejemplares similares
-
Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial
por: Menon, Venu, et al.
Publicado: (2020) -
The cholesteryl ester transfer protein (CETP) raises cholesterol levels in the brain
por: Oestereich, Felix, et al.
Publicado: (2022) -
CYP‐mediated drug–drug interactions with evacetrapib, an investigational CETP inhibitor: in vitro prediction and clinical outcome
por: Cannady, Ellen A., et al.
Publicado: (2015) -
Absolute bioavailability of evacetrapib in healthy subjects determined by simultaneous administration of oral evacetrapib and intravenous [(13)C(8)]‐evacetrapib as a tracer
por: Cannady, Ellen A., et al.
Publicado: (2015) -
Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib
por: Small, David S., et al.
Publicado: (2016)